Oxaliplatin in Unresectable Hepatocellular Carcinoma

NCT00280618 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2009-09-15

No results posted yet for this study

Summary

Primary:

* To determine the Tumor Response Rate of patients with hepatocellular carcinoma treated with the combination chemotherapy of Eloxatin+5-Fluorouracil/Leucovorin

Secondary:

* Safety and tolerability of this regimen in these patients

Conditions

  • Carcinoma, Hepatocellular

Interventions

Sponsors & Collaborators

Principal Investigators

  • Pingkuan Zhang · Sanofi

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-07-31
Primary Completion
2006-11-30

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00280618 on ClinicalTrials.gov